Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...

Ozempic faces over 1,800 lawsuits in US courts, with damages possibly topping $2 billion. Patients allege the drug caused ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

Investing.com -- Danish drugmaker Novo Nordisk (NYSE: NVO) announced Tuesday that Canada’s health regulator has approved its diabetes drug Ozempic for additional uses related to kidney disease.

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

(Reuters) -Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of ...

The viral weight-loss GLP-1 injection is now in the dock with $2 billion lawsuits as patients allege stomach paralysis, ...